Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAT-1251 in Myelofibrosis
NCT04054245Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenumlostat in myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jul 2019; status: withdrawn.
02
Drugs
lenumlostat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04054245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054245.